Orlagh is a Postdoctoral Fellow and Nanomedicine team lead in the Porter Group at Monash Institute of Pharmaceutical Sciences (MIPS). Orlagh commenced her studies at MIPS after five years in startup companies in Dublin. Her postgraduate studies involved the use of PEGylation strategies to influence the rate of digestion of triglycerides, thereby improving the oral bioavailability of poorly water soluble drugs.

More recently, Orlagh's research interests have expanded into cancer and autoimmunity. Specifically, to improve accumulation of nanocarriers and macromolecules at their active site. This is achieved with multiple strategies, including active targeting, stromal modification and manipulation of physicochemical characteristics. Additionally, she is examining how these high molecular weight therapeutics can be redirected to the lymphatic system to better treat lymph-resident diseases.